Eligible patients (≥18 years) must have relapsed/refractory MM/NHL, ECOG 0-2, >3-month life expectancy, and adequate organ function. Exclusions include active CNS involvement, Grade≥2 neuropathy, uncontrolled infections (HBV/HCV/HIV), QTcF≥500ms, prior CD74-targeted therapy, or significant cardiac/pulmonary disease. 18 patients with NHL have been treated at 9 dose levels: .05, .075, .15, .27, .43, .65, .91, 1.27 and 1.78 mg/kg.

Patients with advanced, relapsed/refractory NHL are eligible for enrollment. STRO-001 is administered as a 60-minute IV infusion. STRO-001 was initially administered on Days 1 and 15 of a 28-day cycle. Starting at 0.91 mg/kg, STRO-001 was administered on Day 1 of a 3-week cycle. Treatment is administered until disease progression or unacceptable toxicity.

Eligible patients (≥18 years) must have histologically confirmed B-cell NHL (DLBCL/FL/MZL/MCL) with ≥2 prior therapies (including anti-CD20 regimens), measurable lesions (≥1.5cm nodal/≥1.0cm extranodal), ECOG 0-2. Key exclusions: CNS lymphoma, active HBV/HCV/HIV, QTcF>450/470ms (M/F), CAR-T within 60 days, prior CD74-targeted therapy, or unresolved toxicity >Grade 1 (except alopecia).